Reaction: Tepotinib to 1 product

Reaction
Reaction type
N-demethylation
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Johne A, Scheible H, Becker A, van Lier JJ, Wolna P, Meyring M: Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers. Invest New Drugs. 2020 Oct;38(5):1507-1519. doi: 10.1007/s10637-020-00926-1. Epub 2020 Mar 27. [Article]
Comments
Not Available
Enzymes
Not Available